GRADIENTECH AB

Their core work

Gradientech AB is a Swedish biotech SME based in Uppsala that develops rapid diagnostic systems for clinical microbiology, with their flagship product QuickMIC™ designed to deliver antibiotic susceptibility results far faster than conventional laboratory methods — a capability with direct clinical impact in the fight against antimicrobial resistance. The company sits at the intersection of microfluidics, cell biology, and medical device development, combining scientific depth with a clear product commercialization orientation. Their participation in an MSCA research training network on epithelial cell motility suggests foundational expertise in cell-based assay technology and microenvironment engineering, which underpins their diagnostic platform. As a Uppsala-based company, they operate within one of Europe's strongest life science ecosystems, benefiting from proximity to Uppsala University and SciLifeLab.

What they specialise in

How they've shifted over time

Gradientech's H2020 trajectory, though short, shows a deliberate pivot from scientific participation toward commercial product development. In 2015–2018 they engaged as a partner in a large academic research training network focused on fundamental cell biology, signalling they had relevant technical tools and scientific credibility but were not yet leading product work. By 2018 they stepped into the coordinator role on their own SME Instrument application, staking out QuickMIC™ as a standalone commercial proposition — a clear signal of maturing from research contributor to product company. The two projects together trace a classic deep-tech startup arc: anchor yourself in credible science networks, then convert that expertise into a funded product validation milestone.

Gradientech was heading firmly toward clinical commercialization of QuickMIC™ as of 2018; any future collaboration would likely be in the context of clinical validation, regulatory pathways, or scale-up — not basic research.

How they like to work

Gradientech has played both roles — networked research partner and solo product leader — across just two projects, which reflects a pragmatic approach to EU funding rather than a fixed consortium strategy. Their participation in the large InCeM MSCA network (typically 10–15 institutions) shows they can operate effectively in complex multi-partner consortia, while the SME Instrument grant demonstrates they can lead a focused, company-driven project without a consortium. For a future partner, this suggests a company that is selective and outcome-oriented rather than a habitual consortium builder.

Gradientech has connected with 28 unique consortium partners across 8 countries, a notably wide network for an organization with only 2 projects — reflecting the large, international nature of MSCA Research Training Networks. Their geographic footprint is European, with no strong indication of a single-country cluster.

What sets them apart

Gradientech occupies a rare niche: a research-credentialed SME with a specific, market-ready diagnostic product targeting antimicrobial resistance — one of the highest-priority healthcare challenges in Europe and globally. Unlike academic spin-outs that remain in prototype mode, they secured an SME Instrument grant as coordinator, signalling that they had a defensible business case and a commercial roadmap. For consortium builders in infectious disease diagnostics, point-of-care technologies, or AMR-related health projects, Gradientech offers a combination of scientific legitimacy and product-stage relevance that is uncommon at this company size.

Highlights from their portfolio

• QuickMIC
  Coordinated SME Instrument Phase 1 project for their own commercial product — the clearest signal of a company transitioning from research partner to diagnostic device manufacturer with a specific AMR application.
• InCeM
  Participation in a prestigious MSCA Research Training Network worth EUR 263,659 to the company, providing scientific credibility and a pan-European partner network that informed their later diagnostic platform work.